NASDAQ:ENTAEnanta Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Enanta Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $47.69 +0.64 (+1.36 %) (As of 08/4/2020 04:00 PM ET) Add Compare Share Today's Range$46.48Now: $47.69▼$48.0050-Day Range$45.85MA: $49.82▼$53.5352-Week Range$38.40Now: $47.69▼$75.66Volume176,975 shsAverage Volume197,786 shsMarket Capitalization$953.99 millionP/E Ratio42.58Dividend YieldN/ABeta0.48 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $71.33, Enanta Pharmaceuticals has a potential upside of 49.6% from its current price of $47.69.Amount of Analyst CoverageEnanta Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesEnanta Pharmaceuticals has received 282 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEnanta Pharmaceuticals has received 325 “underperform” votes. (Add your “underperform” vote.)Community SentimentEnanta Pharmaceuticals has received 53.54% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote “Outperform” if you believe ENTA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEnanta Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnanta Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enanta Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.93% of the stock of Enanta Pharmaceuticals is held by insiders.Percentage Held by Institutions88.97% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Enanta Pharmaceuticals are expected to decrease in the coming year, from ($1.09) to ($3.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enanta Pharmaceuticals is 42.58, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 17.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Enanta Pharmaceuticals is 42.58, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.36.Price to Book Value per Share RatioEnanta Pharmaceuticals has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.2Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.29 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENTA Previous Symbol CUSIPN/A CIK1177648 Webwww.enanta.com Phone617-607-0800Debt Debt-to-Equity Ratio0.01 Current Ratio20.64 Quick Ratio20.63Price-To-Earnings Trailing P/E Ratio42.58 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$205.20 million Price / Sales4.65 Cash Flow$2.39 per share Price / Cash Flow19.92 Book Value$23.50 per share Price / Book2.03Profitability EPS (Most Recent Fiscal Year)$2.21 Net Income$46.38 million Net Margins13.46% Return on Equity5.04% Return on Assets4.76%Miscellaneous Employees113 Outstanding Shares20,004,000Market Cap$953.99 million Next Earnings Date8/4/2020 (Confirmed) OptionableOptionable $47.69 +0.64 (+1.36 %) (As of 08/4/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ENTA News and Ratings via Email Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions How has Enanta Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Enanta Pharmaceuticals' stock was trading at $52.92 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ENTA stock has decreased by 9.9% and is now trading at $47.69. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Enanta Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Enanta Pharmaceuticals. When is Enanta Pharmaceuticals' next earnings date? Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Enanta Pharmaceuticals. How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals Inc (NASDAQ:ENTA) issued its earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.73) by $0.43. The biotechnology company earned $27.60 million during the quarter, compared to the consensus estimate of $29.16 million. Enanta Pharmaceuticals had a net margin of 13.46% and a return on equity of 5.04%. The company's quarterly revenue was down 30.3% compared to the same quarter last year. During the same period last year, the company posted $0.20 earnings per share. View Enanta Pharmaceuticals' earnings history. What price target have analysts set for ENTA? 6 Wall Street analysts have issued 1 year price objectives for Enanta Pharmaceuticals' shares. Their forecasts range from $49.00 to $130.00. On average, they expect Enanta Pharmaceuticals' stock price to reach $71.33 in the next year. This suggests a possible upside of 49.6% from the stock's current price. View analysts' price targets for Enanta Pharmaceuticals. Has Enanta Pharmaceuticals been receiving favorable news coverage? Media coverage about ENTA stock has trended somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Enanta Pharmaceuticals earned a news impact score of 0.8 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news about Enanta Pharmaceuticals. Who are some of Enanta Pharmaceuticals' key competitors? Some companies that are related to Enanta Pharmaceuticals include Allakos (ALLK), Amicus Therapeutics (FOLD), FibroGen (FGEN), Opko Health (OPK), ChemoCentryx (CCXI), BridgeBio Pharma (BBIO), Arena Pharmaceuticals (ARNA), PTC Therapeutics (PTCT), Agios Pharmaceuticals (AGIO), CytoDyn (CYDY), Alkermes (ALKS), Principia Biopharma (PRNB), Axsome Therapeutics (AXSM), Insmed (INSM) and Amarin (AMRN). View all competitors. What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), Gilead Sciences (GILD), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), GW Pharmaceuticals PLC- (GWPH) and Netflix (NFLX). Who are Enanta Pharmaceuticals' key executives? Enanta Pharmaceuticals' management team includes the following people: Dr. Jay R. Luly, Pres, CEO & Director (Age 63)Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 64)Dr. Yat Sun Or, Sr. VP of R&D and Chief Scientific Officer (Age 67)Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 65)Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 53) What is Enanta Pharmaceuticals' stock symbol? Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA." Who are Enanta Pharmaceuticals' major shareholders? Enanta Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.24%), Mackay Shields LLC (0.09%), Comerica Bank (0.09%), Strs Ohio (0.07%), SG Americas Securities LLC (0.07%) and Texas Permanent School Fund (0.06%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View institutional ownership trends for Enanta Pharmaceuticals. Which institutional investors are selling Enanta Pharmaceuticals stock? ENTA stock was sold by a variety of institutional investors in the last quarter, including Mackay Shields LLC, Wedge Capital Management L L P NC, and Texas Permanent School Fund. View insider buying and selling activity for Enanta Pharmaceuticals. Which institutional investors are buying Enanta Pharmaceuticals stock? ENTA stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., SG Americas Securities LLC, Hancock Whitney Corp, First Trust Advisors LP, Quantitative Systematic Strategies LLC, First Quadrant L P CA, ProShare Advisors LLC, and Zurcher Kantonalbank Zurich Cantonalbank . View insider buying and selling activity for Enanta Pharmaceuticals. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Enanta Pharmaceuticals' stock price today? One share of ENTA stock can currently be purchased for approximately $47.69. How big of a company is Enanta Pharmaceuticals? Enanta Pharmaceuticals has a market capitalization of $953.99 million and generates $205.20 million in revenue each year. The biotechnology company earns $46.38 million in net income (profit) each year or $2.21 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe. What is Enanta Pharmaceuticals' official website? The official website for Enanta Pharmaceuticals is www.enanta.com. How can I contact Enanta Pharmaceuticals? Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected] This page was last updated on 8/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
